Who are tafluprost/timolol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Travoprost/timolol fixed combination, travoprost, latanoprost/timolol fixed combination drops, Latanoprost/Timolol, Latanoprost/Timolol therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tafluprost-timolol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

tafluprost/timolol — Competitive Intelligence Brief

tafluprost/timolol (tafluprost/timolol) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analog / beta-blocker combination. Area: Ophthalmology.

marketed Prostaglandin analog / beta-blocker combination FP receptor (tafluprost); beta-2 adrenergic receptor (timolol) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

tafluprost/timolol (tafluprost/timolol) — Fondazione G.B. Bietti, IRCCS. Tafluprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor, while timolol is a non-selective beta-blocker that decreases aqueous humor production, together reducing intraocular pressure.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
tafluprost/timolol TARGET	tafluprost/timolol	Fondazione G.B. Bietti, IRCCS	marketed	Prostaglandin analog / beta-blocker combination	FP receptor (tafluprost); beta-2 adrenergic receptor (timolol)
Travoprost/timolol fixed combination, travoprost	Travoprost/timolol fixed combination, travoprost	Aristotle University Of Thessaloniki	marketed	Prostaglandin analog / beta-blocker combination	FP prostaglandin receptor (travoprost); beta-adrenergic receptors (timolol)
latanoprost/timolol fixed combination drops	latanoprost/timolol fixed combination drops	Aristotle University Of Thessaloniki	marketed	Prostaglandin analog / Beta-blocker combination	Prostaglandin F receptor (FP receptor) / Beta-adrenergic receptors (β1 and β2)
Latanoprost/Timolol	Latanoprost/Timolol	Universiti Kebangsaan Malaysia Medical Centre	marketed	Prostaglandin analog / Beta-blocker combination	Prostaglandin F receptor (FP receptor) / Beta-adrenergic receptors (β1, β2)
Latanoprost/Timolol therapy	Latanoprost/Timolol therapy	Aristotle University Of Thessaloniki	marketed	Prostaglandin analog / Beta-blocker combination	Prostaglandin F receptor (FP receptor) / Beta-adrenergic receptors (β1, β2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analog / beta-blocker combination class)

Aristotle University Of Thessaloniki · 1 drug in this class
Fondazione G.B. Bietti, IRCCS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). tafluprost/timolol — Competitive Intelligence Brief. https://druglandscape.com/ci/tafluprost-timolol. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab